Business Context and Reporting Period
Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: DuPont is a global science and technology leader operating in five growth platforms: Agriculture & Nutrition, Coatings & Color Technologies, Electronic & Communication Technologies, Performance Materials, and Safety & Protection, plus a Pharmaceuticals segment. The company employs approximately 60,000 people across 80 countries, with roughly 60% of net sales generated outside the United States.
Key Financial Metrics (2007)
| Metric | 2007 Value | 2006 Value |
|---|---|---|
| Net Sales | $29,378 million | $27,421 million |
| Net Income | $2,988 million | $3,148 million |
| Diluted EPS | $3.22 | $3.38 |
| Operating Cash Flow | $4,290 million | $3,736 million |
| Total Assets | $34,131 million | $31,777 million |
| Total Debt | $7,325 million | $7,530 million |
| Stockholders' Equity | $11,136 million | $9,422 million |
| Working Capital | $4,619 million | $4,930 million |
Note: Total Debt calculated as Short-term borrowings ($1,370M) + Long-term borrowings ($5,955M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% to $29.4 billion, driven by an 11% increase in sales outside the U.S. (benefiting from a weaker U.S. dollar) and a 1% increase in U.S. sales. Volume and local selling prices each increased 2% globally.
- Profitability Decline: Net income decreased 5% to $2.99 billion. This was primarily due to a higher effective tax rate (20.0% in 2007 vs. 5.9% in 2006) and a decrease in "Other income, net."
- Other Income: Decreased $286 million to $1.275 billion. Key factors included a $165 million impairment charge on a polyester films joint venture, lower net exchange gains, and the absence of $90 million in tax contingency reversals and $76 million in insurance recoveries recorded in 2006.
- Cost of Goods Sold (COGS): Increased 6% to $21.6 billion but improved as a percentage of sales (73% in 2007 vs. 75% in 2006) due to productivity initiatives and the absence of 2006 restructuring charges.
- Segment Performance:
- Agriculture & Nutrition: Sales up 14%; Pretax Operating Income (PTOI) up 48% to $894 million (excluding 2006 restructuring charges).
- Safety & Protection: Sales up 3%; PTOI up 11% to $1.2 billion, driven by Kevlar and Nomex sales.
- Performance Materials: Sales up 7%; PTOI up 12% to $626 million, despite a $165 million impairment charge.
Guidance, Outlook, and Risks
2008 Outlook: Management forecasts earnings per share in the range of $3.35 to $3.55. This outlook assumes continued revenue growth in emerging markets and earnings growth across all platforms, moderated by weakness in U.S. housing and North American automotive markets, as well as escalating energy and transportation costs.
Strategic Initiatives:
- Investment in new science for agriculture (e.g., Optimum GAT traits).
- Expansion of Safety & Protection capacity ($500 million Kevlar facility in South Carolina).
- Continued cost productivity gains to fund growth investments.
Key Risks and Contingencies:
- Environmental & Litigation: Significant exposure to PFOA (perfluorooctanoic acid) matters, including a $108 million settlement for a class action in West Virginia and ongoing EPA investigations. Potential liability could range up to two to three times the accrued amount ($357 million).
- Antitrust: Ongoing investigations and fines related to elastomers markets (EU fine of approx. $87 million).
- Pharmaceuticals: Income from Cozaar/Hyzaar is expected to step down significantly starting in 2010 as patents expire.
- Commodity Prices: Volatility in energy and raw material costs could impact margins if not fully passed through to customers.
Investor Verification Checklist
- Impairment Charges: Verify the $165 million write-down of the polyester films joint venture investment and its impact on future segment performance.
- Tax Rate Volatility: Assess the sustainability of the 2007 effective tax rate (20.0%) compared to the anomalously low 2006 rate (5.9%) driven by one-time benefits.
- PFOA Exposure: Review Note 19 for details on the $357 million environmental accrual and the potential for additional liabilities related to PFOA litigation and remediation.
- Pharmaceutical Decline: Confirm the timeline and magnitude of the expected earnings step-down from the Cozaar/Hyzaar collaboration post-2010.
- Share Repurchases: Note the completion of the $5 billion share buyback program in 2007 and the status of the remaining $2 billion plan authorized in 2001.